2 results
Approved WMOCompleted
The primary efficacy variable is the change in PV from baseline as assessed by 3 D ultrasonography after 78 weeks of double-blind treatment with OM 20-40 mg daily compared to ATE 50-100 mg daily.Secondary efficacy variables:Change from baseline PV…
Approved WMOCompleted
Primary Objective: a reduction in bronchoconstriction, measured by auto-PEEP, in patients with AE-COPD. Secondary Objective(s): * To test for a dose-dependency. * Decrease in pulmonary artery pressures* Enhance cardiac output* Measure occurrence of…